In this episode we talk to
Ed Boyer about Kratom, pharmacology, legal status, and discuss recent reports of adverse effects.
* Boyer et al
Self-treatment of opioid withdrawal using kratom (Mitragynia speciosa korth)
*
FDA response to Kratom
*
Bradford Hill Criteria
Take Home Points:
* Kratom is an opioid agonist
* Patients should not mix Kratom with other substances
* Patients at risk of seizures should not use Kratom
* Kratom will not show up on a typical urine drug screen